Seventy to ninety percent of PCTs are identified as TCs and 10-30% as ACs. PCTs are subdivided into typical carcinoids (TCs) and atypical carcinoids (ACs), where TCs lack necrosis and have < 2 mitoses/2 mm 2, and ACs have 2-10 mitoses/2 mm 2 and/or necrosis. PCTs occur frequently in never-smokers, and its molecular etiology is still unclear. The incidence of PCTs is relatively low and comprises approximately 1-2% of lung neoplasms. Pulmonary carcinoid tumors (PCTs) are a member of lung neuroendocrine neoplasm family. The biological functions of these biomarkers warrant further studies. We identified that the expressions of three genes have clinical implications in PCTs. Additionally, 79 mutated genes have been found in nine PCTs where TP53 was the only repeated mutation. #Running anova xlstat freeHigher expressions of CREB5, PTPRB and COL4A3 predicted favorable disease free survival (Hazard ratio: 0.03, 0.19 and 0.36 P value: 0.03, 0.03 and 0.08). We uncovered the target genes that were predicted by at least two prediction tools and overlapped by at least one-half of the top miRNAs, which yielded 44 genes (FC2), respectively. normal tissues) in the top 1% differentially expressed miRNAs, respectively. Resultsįrom the total of 1145 miRNAs, we obtained 16 and 17 miRNAs that showed positive and negative fold changes (FCs, tumors vs. We aimed to identify clinically meaningful biomarkers in pulmonary carcinoid tumors (PCTs), a member of neuroendocrine neoplasms, via profiling miRNAs and mRNAs. MiRNAs play key regulatory roles in cellular pathological processes.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |